Envista Holdings Corporation
Financials
Valuation Metrics
Envista Holdings Corporation's Market Cap is $3.85B. At end of 2025 it was $3.57B. Ranked #1548 of 3,121 in US market (top 50%), #1008 of 1,658 on NYSE (top 61%), #93 of 205 in Health Care Equipment & Services (top 45%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.85B | US#1,548/3,121 Sec#93/205 |
| Revenue | $2.86B | US#1,230/3,121 Sec#75/205 |
| Net Income | $95M | US#1,644/3,121 Sec#84/205 |
| Total Assets | $5.60B | US#1,364/3,121 Sec#65/205 |
| Net Assets | $3.08B | US#953/3,121 Sec#48/205 |
| Employees | 12,000 | US#781/3,121 Sec#59/205 |
| Value | ||
| P/E | 40.56x | US#1,812/3,121 Sec#86/205 |
| P/B | 1.25x | US#642/3,121 Sec#29/205 |
| PEG | 0.53x | US#631/3,121 Sec#25/205 |
| P/S | 1.35x | US#937/3,121 Sec#64/205 |
| EV/EBITDA | 12.29x | US#1,183/3,121 Sec#39/205 |
| FCF Yield | 6.03% | US#1,200/3,121 Sec#52/205 |
| Profitability | ||
| ROE | 3.09% | US#1,964/3,121 Sec#102/205 |
| ROA | 1.70% | US#1,733/3,121 Sec#109/205 |
| Op. Margin | 9.92% | US#1,602/3,121 Sec#80/205 |
| Revenue Growth | 11.89% | US#1,111/3,121 Sec#75/205 |
| Earnings Growth | 76.58% | US#379/3,121 Sec#14/205 |
| Financial Health | ||
| Debt Ratio | 81.94% | US#916/3,121 Sec#91/205 |
| Total Debt | $1.59B | US#1,306/3,121 Sec#65/205 |
| FCF | $232M | US#1,309/3,121 Sec#74/205 |
| Cash | $1.13B | US#616/3,121 Sec#32/205 |
| Current Ratio | 2.43x | US#1,016/3,121 Sec#99/205 |
| Net Debt/EBITDA | 1.32x | US#1,093/3,121 Sec#65/205 |
| Performance | ||
| 1Y Return | 12.87% | US#1,381/3,121 Sec#102/205 |
| 1M Return | -14.88% | US#2,805/3,121 Sec#189/205 |
| From 52W High | -22.16% | US#1,631/3,121 Sec#114/205 |
| 1Y MDD | -25.97% | US#1,117/3,121 Sec#37/205 |
| Trading | ||
| Volume | 4,003,338 shares | US#423/3,121 Sec#19/205 |
| Trading Value | $97M | US#837/3,121 Sec#66/205 |
| Per Share | ||
| EPS | $0.58 | US#1,850/3,121 Sec#101/205 |
| BPS | $18.90 | US#1,297/3,121 Sec#71/205 |
Company Info
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.